iTeos Therapeutics, Inc..
ITOS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
iTeos Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of immuno-oncology therapeutics for patients. The company's pipeline includes EOS-448, an antagonist antibody targeting the adenosine A2A receptor, and inupadenant, an adenosine A2A receptor antagonist. ...Show More
Better Health for All
20
The company's entire product portfolio is dedicated to developing immuno-oncology therapeutics for cancer and an obesity drug, indicating that 100% of its offerings are intended to deliver substantial health benefits, making health impact fundamental to its business decisions.
1
iTeos Therapeutics invested $145.4 million in R&D in FY2024, which represents over 25% of its cash and investments ($655.0 million as of December 31, 2024), demonstrating a revolutionary commitment to health innovation.
2
The company adheres to ethical guidelines for clinical trials, including The Declaration of Helsinki, ICH GCP E6, and national/local regulations, with continuous evaluation of patient safety.
3
However, the company expects to incur $21.8 million to $24.7 million in severance and employee termination costs as it winds down operations, indicating a significant impact on its workforce.
4
There is no evidence regarding the company's approach to patents in relation to global health needs, therefore it is scored as not applicable.
Fair Money & Economic Opportunity
0
iTeos Therapeutics, Inc. is a biopharmaceutical company focused on immuno-oncology.
1
The provided articles do not contain any evidence that the company offers lending, insurance, deposit, or other financial services to consumers.
2
Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable, as the company's core business lies outside the financial sector.
Fair Pay & Worker Respect
0
No evidence available to assess iTeos Therapeutics, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No information regarding ITOS.US's fair trade and ethical sourcing practices, supplier audits, child/forced labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend was found in the provided articles.
Honest & Fair Business
0
No evidence available to assess iTeos Therapeutics, Inc. on Honest & Fair Business.
Kind to Animals
0
No evidence available to assess iTeos Therapeutics, Inc. on Kind to Animals.
No War, No Weapons
0
No evidence available to assess iTeos Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess iTeos Therapeutics, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No evidence available to assess iTeos Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
-40
iTeos Therapeutics has implemented Syskit Point to enhance its Office 365 governance, which includes automated quarterly access reviews for content owners and regular reporting on external sharing.
1
This has led to fewer breaches and access slip-ups, indicating excellent data governance with preventative controls, though not explicitly stating zero incidents.
2
The company has ensured compliance with government regulations due to high standards of sensitive data access control.
3
Furthermore, the company's approach integrates privacy considerations into its operations by actively tracking external collaborators on intellectual property data and enhancing the monitoring of shared files and links.
4
Zero Waste & Sustainable Products
-10
iTeos Therapeutics' Belgian office holds an environmental permit for GMO activities and states it exceeds minimum legal waste management requirements.
1
The company has no reported waste disposal violations or citations in the provided articles.
2
No specific quantitative data is available for waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, product durability, repairability, waste audit frequency, zero-waste certification, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
3